Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PLRX
PLRX logo

PLRX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Pliant Therapeutics Inc (PLRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.160
1 Day change
-1.69%
52 Week Range
1.950
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

PLRX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The setup is weak technically, there is no recent news catalyst, no strong proprietary buy signal, and the options market is extremely bearish. The only supportive factor is hedge fund buying, but that is not enough to outweigh the current risk/reward. My direct view: hold off for now.

Technical Analysis

The short-term trend is bearish. MACD histogram is below zero and still expanding negatively, showing downside momentum. RSI_6 at 35.28 is weak and close to oversold, but not yet a clear reversal signal. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, confirming a downtrend across timeframes. Price at 1.16 is just above support at 1.138 and near S2 at 1.104, while resistance sits at 1.194 and 1.249. The stock trend model suggests a modest near-term bounce potential, but the broader technical picture remains weak.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The options setup is bearish overall. Put open interest of 1,521 vs call open interest of 455 gives a high put-call ratio of 3.34, indicating downside hedging or bearish positioning. Implied volatility is extremely elevated at 913.79 with IV percentile at 100, which signals very high expected movement and speculative pressure. However, today’s option volume is extremely low (only 5 calls and 0 puts), so the sentiment signal is dominated more by open interest than active trading. Overall, options imply bearish-to-defensive sentiment.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
2

Positive Catalysts

  • Hedge funds are buying, with buying amount up 138.46% over the last quarter. The stock is also trading slightly higher pre-market, and the broader market is positive with the S&P 500 up 0.58% pre-market. The stock trend model suggests some short-term upside probability, including a 5.96% chance of gain over the next week and 15.29% over the next month.

Neutral/Negative Catalysts

  • No news in the recent week means there is no current event-driven catalyst. Insiders are neutral with no significant recent activity. Options sentiment is bearish with a 3.34 put-call open interest ratio. Technicals are weak and aligned with a downtrend. No recent congress trading data or influential figure transactions were found. No AI Stock Picker or SwingMax buy signal is present.

Financial Performance

No usable latest-quarter financial snapshot was available due to an error, so there is no reliable quarterly revenue or earnings update to assess. As a result, there is no confirmed growth trend from the provided financial data, which weakens the case for a long-term beginner buy.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target change data was provided, so there is no visible Wall Street upgrade/downgrade trend to support a bullish view. Based on the available information, Wall Street pros would likely be split to cautious: the main pro is hedge fund accumulation, while the main cons are bearish technicals, bearish options positioning, no recent news catalyst, and missing financial confirmation. No recent politician or influential figure buying or selling was reported.

Wall Street analysts forecast PLRX stock price to rise
4 Analyst Rating
Wall Street analysts forecast PLRX stock price to rise
0 Buy
3 Hold
1 Sell
Hold
Current: 1.180
sliders
Low
2
Averages
3
High
4
Current: 1.180
sliders
Low
2
Averages
3
High
4
Canaccord
Hold
downgrade
$4 -> $3
AI Analysis
2026-03-13
Reason
Canaccord
Price Target
$4 -> $3
AI Analysis
2026-03-13
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Pliant Therapeutics to $3 from $4 and keeps a Hold rating on the shares. The firm said Pliant reported financial results and business highlights for 4Q25 and FY2025. As of December 31, 2025, the company had cash and cash equivalents of $192.4M. Management believes that the cash on hand is sufficient to fund planned operations into 2H28.
Piper Sandler
Overweight
to
NULL
downgrade
$4 -> $3
2026-03-12
Reason
Piper Sandler
Price Target
$4 -> $3
2026-03-12
downgrade
Overweight
to
NULL
Reason
Piper Sandler lowered the firm's price target on Pliant Therapeutics to $3 from $4 and keeps an Overweight rating on the shares. At Q4/FY25 earnings, Pliant provided a thoughtful update to their PLN-101095 program, the firm notes. Specifically, management detailed they have begun an accelerated development plan for PLN-101095 inclusive of beginning initiation activities for an open-label Phase 1b indication expansion trial which has first patient enrollment expected Q2 2026 and interim data 2027. Piper believes 2026 will be an informative year for Pliant as they continue to progress PLN-101095 development based on key Phase 1 data which will be presented at AACR 2026.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PLRX
Unlock Now

People Also Watch